All Stories

  1. The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer

    Article • Gynecologic Oncology, November 2014, Elsevier

    Dr Andrew B Nixon

  2. A Phase Ib Study of Combined VEGFR and mTOR Inhibition With Vatalanib and Everolimus in Patients With Advanced Renal Cell Carcinoma

    Article • Clinical Genitourinary Cancer, August 2014, Elsevier

    Dr Andrew B Nixon

  3. Effects of the combination of TRC105 and bevacizumab on endothelial cell biology

    Article • Investigational New Drugs, July 2014, Springer Science + Business Media

    Dr Andrew B Nixon

  4. Integrative Pathway Analysis Using Graph-Based Learning with Applications to TCGA Colon and Ovarian Data

    Article • Cancer Informatics, July 2014, Libertas Academica, Ltd.

    Dr Andrew B Nixon

  5. Ectodomain shedding of T RIII is required for T RIII-mediated suppression of TGF-  signaling and breast cancer migration and invasion

    Article • Molecular Biology of the Cell, June 2014, American Society for Cell Biology (ASCB)

    Dr Andrew B Nixon

  6. The Balance of Cell Surface and Soluble Type III TGF-β Receptor Regulates BMP Signaling in Normal and Cancerous Mammary Epithelial Cells

    Article • Neoplasia, June 2014, Elsevier

    Dr Andrew B Nixon

  7. Role of TGF-  receptor III localization in polarity and breast cancer progression

    Article • Molecular Biology of the Cell, May 2014, American Society for Cell Biology (ASCB)

    Dr Andrew B Nixon

  8. Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors

    Article • Investigational New Drugs, April 2014, Springer Science + Business Media

    Dr Andrew B Nixon

  9. Modulation of circulating protein biomarkers following TRC105 (anti‐endoglin antibody) treatment in patients with advanced cancer

    Article • Cancer Medicine, February 2014, Wiley

    Dr Andrew B Nixon

  10. Dasatinib (BMS-35482) Interacts Synergistically With Docetaxel, Gemcitabine, Topotecan, and Doxorubicin in Ovarian Cancer Cells With High SRC Pathway Activation and Protein Expression

    Article • International Journal of Gynecological Cancer, February 2014, BMJ

    Dr Andrew B Nixon

  11. Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer

    Article • Investigational New Drugs, November 2013, Springer Science + Business Media

    Dr Andrew B Nixon

  12. Type III TGF-β receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma

    Article • Journal of Clinical Investigation, October 2013, American Society for Clinical Investigation

    Dr Andrew B Nixon

  13. Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance)

    Article • Clinical Cancer Research, October 2013, American Association for Cancer Research (AACR)

    Dr Andrew B Nixon

  14. Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-β signaling

    Article • Oncogene, September 2013, Springer Science + Business Media

    Dr Andrew B Nixon

  15. Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment

    Article • Journal of Clinical Investigation, August 2013, American Society for Clinical Investigation

    Dr Andrew B Nixon

  16. A phase I study of ABT‐510 plus bevacizumab in advanced solid tumors

    Article • Cancer Medicine, March 2013, Wiley

    Dr Andrew B Nixon

  17. Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab

    Article • Cancer Medicine, March 2013, Wiley

    Dr Andrew B Nixon

  18. A Phase II Study of Capecitabine, Oxaliplatin, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas

    Article • The Oncologist, March 2013, Alphamed Press

    Dr Andrew B Nixon

  19. Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer

    Article • Anti-Cancer Drugs, March 2013, Wolters Kluwer Health

    Dr Andrew B Nixon

  20. Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors

    Article • Cancer Chemotherapy and Pharmacology, June 2012, Springer Science + Business Media

    Dr Andrew B Nixon

  21. Effect of Pazopanib on Tumor Microenvironment and Liposome Delivery

    Article • Molecular Cancer Therapeutics, June 2010, American Association for Cancer Research (AACR)

    Dr Andrew B Nixon

  22. Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression

    Article • Hypertension, September 2009, Wolters Kluwer Health

    Dr Andrew B Nixon

  23. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients

    Article • Cancer Immunology Immunotherapy, January 2008, Springer Science + Business Media

    Dr Andrew B Nixon

  24. A Role for Gz in Pancreatic Islet  -Cell Biology

    Article • Journal of Biological Chemistry, July 2005, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Andrew B Nixon

  25. Analysis of the Regulation of Microtubule Dynamics by Interaction of RGSZ1 (RGS20) with the Neuronal Stathmin, SCG10

    Article • January 2004, Elsevier

    Dr Andrew B Nixon

  26. HDAC6 is a microtubule-associated deacetylase

    Article • Nature, May 2002, Springer Science + Business Media

    Dr Andrew B Nixon

  27. The Interaction of RGSZ1 with SCG10 Attenuates the Ability of SCG10 to Promote Microtubule Disassembly

    Article • Journal of Biological Chemistry, March 2002, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Andrew B Nixon

  28. Phosphorylation and Nuclear Translocation of a Regulator of G Protein Signaling (RGS10)

    Article • Journal of Biological Chemistry, July 2001, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Andrew B Nixon

  29. Acetyl-CoA:1-O-Alkyl-2-lyso-sn-glycero-3-phosphocholine Acetyltransferase Is Directly Activated by p38 Kinase

    Article • Journal of Biological Chemistry, February 1999, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Andrew B Nixon

  30. Differential activation of human neutrophil cytosolic phospholipase A2 and secretory phospholipase A2 during priming by 1,2-diacyl- and 1-O-alkyl-2-acylglycerols

    Article • Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, November 1998, Elsevier

    Dr Andrew B Nixon

  31. Comparison of alkylacylglycerol vs. diacylglycerol as activators of mitogen-activated protein kinase and cytosolic phospholipase A2 in human neutrophil priming

    Article • Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, August 1997, Elsevier

    Dr Andrew B Nixon

  32. 5-Oxo-eicosanoids and Hematopoietic Cytokines Cooperate in Stimulating Neutrophil Function and the Mitogen-activated Protein Kinase Pathway

    Article • Journal of Biological Chemistry, July 1996, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Andrew B Nixon

  33. Comparison of acceptor and donor substrates in the CoA-independent transacylate reaction in human neutrophils

    Article • Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, May 1996, Elsevier

    Dr Andrew B Nixon

  34. Activation of 85 kDa PLA2 by Eicosanoids in Human Neutrophils and Eosinophils

    Article • January 1996, Springer Science + Business Media

    Dr Andrew B Nixon

  35. The Targeting of Leukocytes by 5-Oxo-Eicosanoids

    Article • January 1996, Springer Science + Business Media

    Dr Andrew B Nixon

  36. 5-Lipoxygenase Products Modulate the Activity of the 85-kDa Phospholipase A2 in Human Neutrophils

    Article • Journal of Biological Chemistry, November 1995, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Andrew B Nixon

  37. Evaluation of phospholipase C and D activity in stimulated human neutrophils using a phosphono analog of choline phosphoglyceride

    Article • Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, July 1993, Elsevier

    Dr Andrew B Nixon

  38. A facile synthesis of 1-O-alkyl-2-(R)-hydroxypropane-3-phosphonocholine (lyso-phosphono-platelet activating factor)

    Article • Chemistry and Physics of Lipids, October 1992, Elsevier

    Dr Andrew B Nixon